RGS16 regulated by let-7c-5p promotes glioma progression by activating PI3K-AKT pathway
Chaochao Wang1,2, Hao Xue1,2, Rongrong Zhao1,2, Zhongzheng Sun2,3, Xiao Gao1,2, Yanhua Qi1,2, Huizhi Wang1,2, Jianye Xu1,2, Lin Deng1,2(), Gang Li1,2()
1. Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan 250012, China 2. Shandong Key Laboratory of Brain Function Remodeling, Jinan 250012, China 3. The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, China
Gliomas are the most common central nervous system tumours; they are highly aggressive and have a poor prognosis. RGS16 belongs to the regulator of G-protein signalling (RGS) protein family, which plays an important role in promoting various cancers, such as breast cancer, pancreatic cancer, and colorectal cancer. Moreover, previous studies confirmed that let-7c-5p, a well-known microRNA, can act as a tumour suppressor to regulate the progression of various tumours by inhibiting the expression of its target genes. However, whether RGS16 can promote the progression of glioma and whether it is regulated by miR let-7c-5p are still unknown. Here, we confirmed that RGS16 is upregulated in glioma tissues and that high expression of RGS16 is associated with poor survival. Ectopic deletion of RGS16 significantly suppressed glioma cell proliferation and migration both in vitro and in vivo. Moreover, RGS16 was validated as a direct target gene of miR let-7c-5p. The overexpression of miR let-7c-5p obviously downregulated the expression of RGS16, and knocking down miR let-7c-5p had the opposite effect. Thus, we suggest that the suppression of RGS16 by miR let-7c-5p can promote glioma progression and may serve as a potential prognostic biomarker and therapeutic target in glioma.
GP Dunn, ML Rinne, J Wykosky, G Genovese, SN Quayle, IF Dunn, PK Agarwalla, MG Chheda, B Campos, A Wang, C Brennan, KL Ligon, F Furnari, WK Cavenee, RA Depinho, L Chin, WC Hahn. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26(8): 756–784 https://doi.org/10.1101/gad.187922.112
pmid: 22508724
2
C Villa, C Miquel, D Mosses, M Bernier, AL Di Stefano. The 2016 World Health Organization classification of tumours of the central nervous system. Presse Med 2018; 47(11–12): e187–e200 https://doi.org/10.1016/j.lpm.2018.04.015
pmid: 30449638
3
F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424 https://doi.org/10.3322/caac.21492
pmid: 30207593
EM Ross, TM Wilkie. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69(1): 795–827 https://doi.org/10.1146/annurev.biochem.69.1.795
pmid: 10966476
6
KM Druey, KJ Blumer, VH Kang, JH Kehrl. Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. Nature 1996; 379(6567): 742–746 https://doi.org/10.1038/379742a0
pmid: 8602223
7
G Liang, G Bansal, Z Xie, KM Druey. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem 2009; 284(32): 21719–21727 https://doi.org/10.1074/jbc.M109.028407
pmid: 19509421
8
EN Johnson, TM Seasholtz, AA Waheed, B Kreutz, N Suzuki, T Kozasa, TL Jones, JH Brown, KM Druey. RGS16 inhibits signalling through the G alpha 13-Rho axis. Nat Cell Biol 2003; 5(12): 1095–1103 https://doi.org/10.1038/ncb1065
pmid: 14634662
9
M Berthebaud, C Rivière, P Jarrier, A Foudi, Y Zhang, D Compagno, A Galy, W Vainchenker, F Louache. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood 2005; 106(9): 2962–2968 https://doi.org/10.1182/blood-2005-02-0526
pmid: 15998835
10
MB Carper, J Denvir, G Boskovic, DA Primerano, PP Claudio. RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes Cancer 2014; 5(11–12): 420–435 https://doi.org/10.18632/genesandcancer.43
pmid: 25568667
11
N Miyoshi, H Ishii, M Sekimoto, Y Doki, M Mori. RGS16 is a marker for prognosis in colorectal cancer. Ann Surg Oncol 2009; 16(12): 3507–3514 https://doi.org/10.1245/s10434-009-0690-3
pmid: 19760045
12
X Sun, C Charbonneau, L Wei, Q Chen, RM Terek. miR-181a targets RGS16 to promote chondrosarcoma growth, angiogenesis, and metastasis. Mol Cancer Res 2015; 13(9): 1347–1357 https://doi.org/10.1158/1541-7786.MCR-14-0697
pmid: 26013170
X Fu, X Mao, Y Wang, X Ding, Y Li. Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer. Oncol Rep 2017; 38(3): 1851–1856 https://doi.org/10.3892/or.2017.5839
pmid: 28731186
R Huang, G Li, Z Zhao, F Zeng, K Zhang, Y Liu, K Wang, H Hu. RGS16 promotes glioma progression and serves as a prognostic factor. CNS Neurosci Ther 2020; 26(8): 791–803 https://doi.org/10.1111/cns.13382
pmid: 32319728
19
I Chu, J Sun, A Arnaout, H Kahn, W Hanna, S Narod, P Sun, CK Tan, L Hengst, J Slingerland. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007; 128(2): 281–294 https://doi.org/10.1016/j.cell.2006.11.049
pmid: 17254967
20
G Choe, S Horvath, TF Cloughesy, K Crosby, D Seligson, A Palotie, L Inge, BL Smith, CL Sawyers, PS Mischel. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63(11): 2742–2746
pmid: 12782577
21
L Wang, ZG Zhang, RL Zhang, SR Gregg, A Hozeska-Solgot, Y LeTourneau, Y Wang, M Chopp. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006; 26(22): 5996–6003 https://doi.org/10.1523/JNEUROSCI.5380-05.2006
pmid: 16738242
22
QW Fan, C Cheng, C Hackett, M Feldman, BT Houseman, T Nicolaides, D Haas-Kogan, CD James, SA Oakes, J Debnath, KM Shokat, WA Weiss. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 3(147): ra81 https://doi.org/10.1126/scisignal.2001017
pmid: 21062993
23
Y Suzuki, K Shirai, K Oka, A Mobaraki, Y Yoshida, SE Noda, M Okamoto, Y Suzuki, J Itoh, H Itoh, S Ishiuchi, T Nakano. Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J Radiat Res (Tokyo) 2010; 51(3): 343–348 https://doi.org/10.1269/jrr.09109
pmid: 20410674
24
G Choe, S Horvath, TF Cloughesy, K Crosby, D Seligson, A Palotie, L Inge, BL Smith, CL Sawyers, PS Mischel. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63(11): 2742–2746
pmid: 12782577
25
H Mure, K Matsuzaki, KT Kitazato, Y Mizobuchi, K Kuwayama, T Kageji, S Nagahiro. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro-oncol 2010; 12(3): 221–232 https://doi.org/10.1093/neuonc/nop026
pmid: 20167810
M Piwecka, K Rolle, A Belter, AM Barciszewska, M Żywicki, M Michalak, S Nowak, MZ Naskręt-Barciszewska, J Barciszewski. Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol 2015; 9(7): 1324–1340 https://doi.org/10.1016/j.molonc.2015.03.007
pmid: 25864039
